Novartis Ag · SIX:NOVN
Novartis — Q3 2026 Earnings Presentation
91 slides from Novartis's earnings presentation, Oct 27, 2026
Slide 1: Q3 2026 Results
Content Click below to navigate Investor presentation through the document October 27, 2026 Company overview Financial review Conclusions Appendix References Q3 2026 Results Novartis Q3 Results | October 27, 2026 1
Slide 2: Disclaimer
Content Click below to navigate through the document Disclaimer Company overview Financial review This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potenti
Slide 3: Company overview
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Company overview Vas Narasimhan, M.D. Chief Executive Officer Novartis Q3 Results | October 27, 2026 3
Slide 4: Sales growth and core margin expansion in Q3, upgraded FY 2026 guidance
Content Click below to navigate through the document Novartis delivered sales growth and core margin expansion in Q3, 1 Company overview supporting an upgrade to FY 2026 bottom-line guidance Financial review Conclusions USD bn, % cc1 Q3 pipeline highlights Appendix +4% +10% Remibrutinib positive PhI
Slide 5: Priority brands and launches continued strong growth
GROWTH Content Click below to navigate through the document Priority brands and launches continued to show strong growth, Company overview demonstrating the replacement power of the business Financial review Conclusions Q3 Sales Appendix Sales Growth vs. PY Growth vs. PY USD million USD million cc1
Slide 6: Kisqali Q3 sales grew +37% cc
GROWTH Content Click below to navigate through the document Kisqali Q3 sales grew +37% cc, continuing to outperform CDK4/6 market ® Company overview Financial review Conclusions Sales evolution US eBC NBRx 1 Kisqali Competitor 1 Competitor 2 US: +38% in Q3, USD 3bn+ YTD Appendix USD m, % cc 80% • eB
Slide 7: Kesimpta Q3 sales grew +22% cc
GROWTH Content Click below to navigate through the document Kesimpta Q3 sales grew +22% cc, fueled by continued strong demand ® Company overview Financial review Conclusions Sales evolution US: +21% cc in Q3 Appendix USD m, % cc • TRx growth1 outpacing the market, +3%pts in MS (~16% share) and +4.5%
Slide 8: Pluvicto Q3 sales grew +20% cc
GROWTH Content Click below to navigate through the document Pluvicto Q3 sales grew +20% cc, driven by strong ex-US momentum and ® Company overview US pre-taxane growth Financial review Conclusions Sales evolution US: +9% in Q3 Appendix USD m, % cc • Growth driven by pre-taxane setting (70% of busine
Slide 9: Promising early indicators for PSMAddition launch in US
GROWTH Content Click below to navigate through the document Promising early indicators for PSMAddition launch in US Company overview Financial review Conclusions Strong foundation in place Launch dynamics Appendix • >2/3 mAPMN/S (mHSPC) • Expect 5-10 weeks lead-time References Infusion patients mana
Slide 10: Leqvio grew +63% cc in Q3
GROWTH Content Click below to navigate through the document Leqvio grew +63% cc in Q3, reflecting strong demand around the world ® Company overview Financial review Conclusions Sales evolution US: +60% in Q3, outgrowing advanced lipid-lowering market1,2,3 Appendix USD m, % cc • MOTRx growth (+60%) a
Slide 11: Scemblix Q3 sales grew +67% cc
GROWTH Content Click below to navigate through the document Scemblix Q3 sales grew +67% cc, driven by strong US momentum ® Company overview Financial review Conclusions Sales evolution US 1L NBRx Share (R3M)1 US: +78% in Q3 Appendix USD m, % cc Com petitor 1 Scemblix Com petitor 2 Com petitor 3 Com
Slide 12: Cosentyx Q3 sales grew +9% cc
GROWTH Content Click below to navigate through the document Cosentyx Q3 sales grew +9% cc, with growth in HS and SpA indications ® Company overview Financial review Conclusions Sales evolution US HS Naive NBRx Share (R4W)1 US: +9% in Q3 Appendix USD m, % cc Com petitor 1 (molecule 1) Com petitor 2 C
Slide 13: Rhapsido CSU launch momentum; FDA approval in SD
GROWTH Content Click below to navigate through the document Rhapsido CSU launch momentum continued in Q3; FDA approval ® Company overview in symptomatic dermographism (SD) supports expansion into CIndU Financial review Conclusions CSU CIndU Appendix References Strong launch trajectory in US Building
Slide 14: Important readouts for remibrutinib, del-desiran and pelacarsen
INNOVATION Content Click below to navigate through the document Important readouts for remibrutinib, del-desiran and pelacarsen in Q3 Company overview Financial review Conclusions Remibrutinib Del-desiran Pelacarsen Appendix Phase III REMODEL-1 and -2 in RMS Phase III HARBOR in DM1 Phase III HORIZON
Slide 15: REMODEL: Remibrutinib comprehensive disease control and favorable safety
INNOVATION Content Click below to navigate through the document REMODEL: Remibrutinib offers comprehensive disease control and a robust Company overview favorable safety profile, without chronic B-cell depletion Financial review Conclusions Remibrutinib delivered comprehensive …with a robust favorab
Slide 16: Remibrutinib potential USD 4bn+ medicine in RMS
INNOVATION Content Click below to navigate through the document Remibrutinib has the potential to be a USD 4bn+ medicine in RMS, Company overview with potential further upside from nrSPMS Financial review Conclusions RMS+nrSPMS patients treated globally Appendix 2025 ~85k ~85K References ~440k ~40k
Slide 17: Multiple readouts still expected in 2026, strong catalyst path in 2027
INNOVATION Content Click below to navigate through the document Multiple readouts still expected in 2026, with a strong catalyst path in 2027 Company overview Financial review Conclusions Select assets (expected) Appendix Readouts 2026 ianalumab 1L ITP Regulatory 2026 Cosentyx® PMR approval (US) Leq
Slide 18: Financial review and 2026 guidance
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Financial review and 2026 guidance Mukul Mehta Chief Financial Officer Novartis Q3 Results | October 27, 2026 18
Slide 19: Q3 performance with net sales growth +4% cc
FINANCIAL PROFILE Content Click below to navigate through the document Q3 performance with net sales growth at +4% cc and strong core margin 1 1 Company overview expansion Financial review Conclusions Key figures1 Change vs. PY Change vs. PY Q3 Q3 9M 9M Appendix USD million, unless indicated otherwi
Slide 20: Shareholder-friendly capital allocation strategy
FINANCIAL PROFILE Content Click below to navigate through the document Continuing our shareholder-friendly capital allocation strategy Company overview Financial review Conclusions Appendix Investing in the business Returning capital to shareholders References Investments in organic business Consist
Slide 21: Raising 2026 full year core operating income guidance
FINANCIAL PROFILE Content Click below to navigate through the document Raising Novartis 2026 full year core operating income guidance 1 Company overview Financial review Conclusions Expected, barring unforeseen events; growth vs. PY in cc1 Appendix Net Core1 operating expected to be in line to expec
Slide 22: H2 with strengthened performance and accelerated sales growth
FINANCIAL PROFILE Content Click below to navigate through the document H2 with strengthened performance and accelerated quarterly sales growth Company overview Financial review Conclusions 2026 growth vs. PY (cc)1 Appendix Illustrative References 1. Constant currencies (cc) and core results are non-
Slide 23: Expected currency impact for 2026 and 2027
FINANCIAL PROFILE Content Click below to navigate through the document Expected currency impact for full year 2026 and 2027 Company overview Financial review Conclusions Currency impact vs. PY Appendix %pts, assuming late-October exchange rates prevail in 2026 and 2027 References 1. Core results are
Slide 24: Conclusions
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Conclusions Vas Narasimhan, M.D. Chief Executive Officer Novartis Q3 Results | October 27, 2026 24
Slide 25: Conclusions: sales growth, pipeline progress, upgraded guidance
Content Click below to navigate through the document Company overview Financial review Delivered sales growth in Q3 driven by Upgraded full-year guidance priority brands and launches, demonstrating for core operating income following Conclusions the replacement power of the business strong bottom-li
Slide 26: Meet Novartis Management
Content Click below to navigate through the document Upcoming investor event Company overview Financial review Conclusions Appendix Meet Novartis Management References Mid-term guidance 2026-2031 Breakout sessions by therapeutic area and long-term outlook Panel session on AI in R&D Updated peak sale
Slide 27: Appendix
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations References Appendix Novartis Q3 Results | October 27, 2026 27
Slide 28: Key innovation milestones in 2026
INNOVATION Content Click below to navigate through the document Key innovation milestones in 2026 Company overview 2026 selected key events (expected) H1 2026 H2 2026 Status as of end Q3 Rhapsido® CIndU3 US US approval in October Financial review Regulatory Pluvicto® mAPMN/S US, JP, CN US & CN appro
Slide 29: Our pipeline projects at a glance
INNOVATION Content Click below to navigate through the document Our pipeline projects at a glance Company overview Financial review Conclusions Phase I/II Phase III Registration Total Appendix Innovation: Pipeline overview Oncology 19 9 1 29 Financial performance Innovation: Clinical trials Solid tu
Slide 30: Novartis pipeline in Phase I
INNOVATION 17 lead indications Content Click below to navigate through the document Novartis pipeline in Phase I Lead indication Oncology Neuroscience Company overview Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) Solid tumors EDK060 EDK060 - Charcot-Marie-Tooth disease Financi
Slide 31: Novartis pipeline in Phase II
INNOVATION 22 lead indications Content Click below to navigate through the document Novartis pipeline in Phase II Lead indication Oncology Immunology Company overview Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) Solid tumors DDY391 DDY391 VAV1-directed MGD Psoriatic arthritis
Slide 32: Novartis pipeline in Phase III
INNOVATION 8 lead indications Content Click below to navigate through the document Novartis pipeline in Phase III Lead indication Oncology Neuroscience Company overview Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) Solid tumors BAF312 Mayzent® S1P1,5 receptor modulator Multiple
Slide 33: Novartis pipeline in registration
INNOVATION 4 lead indications Content Click below to navigate through the document Novartis pipeline in registration Lead indication Oncology Company overview Code Name Mechanism Indication(s) Hematology Financial review DAK539 pelabresib1 BET inhibitor Myelofibrosis Conclusions Neuroscience Code Na
Slide 34: Novartis submission schedule: new molecular entities
INNOVATION Content Click below to navigate through the document Novartis submission schedule New Molecular Entities: Lead and supplementary indications Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2026 2027 2028 ≥2029 Conclusions del-zota zigakibart 225
Slide 35: Novartis submission schedule: existing brands
INNOVATION Content Click below to navigate through the document Novartis submission schedule Supplementary indications for existing brands Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2026 2027 2028 ≥2029 Conclusions Cosentyx® Fabhalta® Lutathera ® Fabha
Slide 36: Net debt increased by USD 15.5bn
Content Click below to navigate through the document Net debt increased by USD 15.5bn as the FCF was more than offset mainly 1 Company overview by M&A and the annual dividend payment Financial review Conclusions USDbn -15.5 Appendix Innovation: Pipeline overview Financial performance Innovation: Cli
Slide 37: IR Clinical Studies
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview IR Clinical Studies Financial performance Innovation: Clinical trials Clinical Trials Update > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience
Slide 38: Cardiovascular, Renal and Metabolic
Content Click below to navigate through the document Company overview Financial review Cardiovascular, Conclusions Appendix Cardiovascular, Innovation: Pipeline overview RenalRenal andandMetabolic Financial performance Innovation: Clinical trials Metabolic > C ardiovascular, Renal and Metabolic > I
Slide 39: abelacimab – FXI/FXIa inhibitor
Content abelacimab – FXI/FXIa inhibitor Click below to navigate through the document Company overview NCT05712200 LILAC-TIMI 76 (CMAA868A2302) Financial review Indication Stroke prevention in atrial fibrillation (SPAF) Phase Phase 3 Conclusions Patients 2500 Primary Efficacy: Time to first event of
Slide 40: atrasentan – ETA receptor antagonist
Content atrasentan – ETA receptor antagonist Click below to navigate through the document Company overview NCT04573478 ALIGN (CHK01-01) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 404 Primary 1) Double-blind period: Change in proteinuria: the change in urine protei
Slide 41: DII235 – siRNA targeting Lp(a) mRNA
Content DII235 – siRNA targeting Lp(a) mRNA Click below to navigate through the document Company overview NCT07235046 (CDII235A12201) Financial review Indication Risk reduction in cardiovascular disease w elevated Lp(a) Phase Phase 2b Conclusions Patients 234 Primary 1) Time averaged percentage chan
Slide 42: Fabhalta – CFB inhibitor
Content Fabhalta® – CFB inhibitor Fabhalta® – CFB inhibitor Click below to navigate through the document Company overview NCT04578834 APPLAUSE-IgAN (CLNP023A2301) NCT05755386 APPARENT (CLNP023B12302) Financial review Indication IgA nephropathy Indication Immune complex-mediated membranoproliferative
Slide 43: Leqvio – siRNA (regulation of LDL-C)
Content Leqvio® – siRNA (regulation of LDL-C) Click below to navigate through the document Company overview NCT03705234 ORION-4 (CKJX839B12301) NCT05030428 VICTORION-2P (CKJX839B12302) Financial review Indication Secondary prevention of cardiovascular events in patients with elevated levels of Indic
Slide 44: Leqvio – siRNA (regulation of LDL-C)
Content Leqvio® – siRNA (regulation of LDL-C) Click below to navigate through the document Company overview NCT05739383 VICTORION-1P (CKJX839D12302) Financial review Indication CVRR (Primary prevention) Phase Phase 3 Conclusions Patients 14012 Primary Time to the first occurrence of 4P-MACE Appendix
Slide 45: LTP001 – SMURF1 Inhibitor
Content LTP001 – SMURF1 Inhibitor Click below to navigate through the document Company overview NCT06649110 (CLTP001A12202) Financial review Indication Pulmonary arterial hypertension Phase Phase 2 Conclusions Patients 232 Primary Part A- Number of participants with Adverse events (AEs) and Serious
Slide 46: PAC001 – anti-IL6 mAb
Content PAC001 – anti-IL6 mAb Click below to navigate through the document Company overview NCT06362759 TRANQUILITY (CPAC001A12201) Financial review Indication ASCVD Phase Phase 2 Conclusions Patients 143 Primary Evaluate the effects of TOUR006 compared with placebo on hs-CRP Appendix Outcome Innova
Slide 47: pelacarsen – ASO targeting Lp(a)
Content pelacarsen – Antisense oligonucleotide (ASO) Click below to navigate targeting Lp(a) through the document Company overview NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Financial review Indication Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a) Con
Slide 48: QCZ484 – AGT siRNA
Content QCZ484 – AGT siRNA Click below to navigate through the document Company overview NCT06857955 (CQCZ484A12201) Financial review Indication Hypertension Phase Phase 2 Conclusions Patients 396 Primary Change from baseline at Month 3 in mean 24hr systolic blood pressure (SBP) by Appendix Outcome
Slide 49: zigakibart – Anti-APRIL
Content zigakibart – Anti-APRIL Click below to navigate through the document Company overview NCT05852938 BEYOND (CFUB523A12301) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 383 Primary Change from Baseline to week 104 in eGFR Appendix Outcome Innovation: Pipeline o
Slide 50: YMI024 – NLRP3 inhibitor
Content YMI024 – NLRP3 inhibitor Click below to navigate through the document Company overview NCT07830719 (CYMI024A12202) Financial review Indication Risk reduction in cardiovascular disease Phase Phase 2b Conclusions Patients 180 Primary Change from baseline in log-transformed IL-6 Appendix Outcom
Slide 51: Immunology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Immunology Financial performance Innovation: Clinical trials Immunology > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncology > I n-mar
Slide 52: DDY391 – VAV1-directed MGD
Content DDY391 – VAV1-directed MGD Click below to navigate through the document Company overview NCT07801495 (CDDY391A12201) Financial review Indication Psoriatic arthritis Phase Phase 2 Conclusions Patients 220 Primary Outcome 1) Part A: Number of participants achieving American College of Rheumato
Slide 53: DDY391 – VAV1-directed MGD
Content DDY391 – VAV1-directed MGD Click below to navigate through the document Company overview NCT07737743 (CDDY391B12201) Financial review Indication Sjögren's Disease Phase Phase 2 Conclusions Patients 334 Primary Outcome 1) Part A and B: Change from baseline in ESSDAI score at week 24 Appendix
Slide 54: GHZ339 – IL-13, IL-18 inhibitor
Content GHZ339 – IL-13, IL-18 inhibitor Click below to navigate through the document Company overview NCT06947993 PLATFORM-AD (CADPT17A12201) Financial review Indication Atopic dermatitis Phase Phase 2 Conclusions Patients 224 Primary Outcome Change from baseline in the Eczema Area and Severity Inde
Slide 55: GIA632 – IL-15 mAb
Content GIA632 – IL-15 mAb Click below to navigate through the document Company overview NCT07431177 (CGIA632B12201) NCT07220577 (CGIA632A12201) Financial review Indication Non-segmental Vitiligo Indication Atopic dermatitis Phase Phase 2 Phase Phase 2 Conclusions Patients 210 Patients 34 Primary Pe
Slide 56: GIA632 – IL-15 mAb
Content GIA632 – IL-15 mAb Click below to navigate through the document Company overview NCT07775924 ELIPSI (CGIA632C12201) Financial review Indication Lichen planus Phase Phase 2 Conclusions Patients 259 Primary Outcome Number of participants achieving an Investigator Global Assessment (IGA) respon
Slide 57: ianalumab – BAFF-R inhibitor (SIRIUS-LN)
Content ianalumab – BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT05126277 SIRIUS-LN (CVAY736K12301) Financial review Indication Lupus Nephritis Phase Phase 3 Conclusions Patients 452 Primary Outcome Frequency and percentage of parti
Slide 58: ianalumab – BAFF-R inhibitor (SIRIUS-SLE)
Content ianalumab – BAFF-R inhibitor, ADCC-mediated B-cell ianalumab – BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor depletor through the document Company overview NCT05639114 SIRIUS-SLE 1 (CVAY736F12301) NCT05624749 SIRIUS-SLE 2 (CVAY736F12302) Financial review Indication
Slide 59: ianalumab – BAFF-R inhibitor (VENUSS)
Content ianalumab – BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT06470048 VENUSS (CVAY736S12201) Financial review Indication Systemic sclerosis Phase Phase 2 Conclusions Patients 200 Primary 3/5 Revised Composite Response Index in S
Slide 60: ianalumab – BAFF-R inhibitor (THALASSA)
Content ianalumab – BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT07621809 THALASSA (CVAY736A22301) Financial review Indication Sjögren´s Disease (high symptom burden) Phase Phase 3 Conclusions Patients 570 Primary Change in baseline
Slide 61: Rhapsido – BTK inhibitor
Content Rhapsido® – BTK inhibitor Click below to navigate through the document Company overview NCT05976243 RemIND (CLOU064M12301) Financial review Indication Chronic inducible urticaria Phase Phase 3 Conclusions Patients 362 Primary 1. Proportion of participants with complete response in Total Fric
Slide 62: Rhapsido – BTK inhibitor
Content Rhapsido® – BTK inhibitor Click below to navigate through the document Company overview NCT07768371 (CLOU064I12301) Financial review Indication Food allergy Phase Phase 3 Conclusions Patients 576 Primary Outcome Measures Sub-study 1: Number of participants achieving response status (tolerate
Slide 63: Rhapsido – BTK inhibitor
Content Rhapsido® – BTK inhibitor Click below to navigate through the document Company overview NCT06799000 RECHARGE1 (CLOU064J12301) NCT06840392 RECHARGE2 (CLOU064J12302) Financial review Indication Hidradenitis suppurativa Indication Hidradenitis suppurativa Phase Phase 3 Phase Phase 3 Conclusions
Slide 64: Rhapsido – BTK inhibitor
Content Rhapsido® – BTK inhibitor Click below to navigate through the document Company overview NCT07700056 (CLOU064R12301) NCT07811869 (CLOU064R12302) Financial review Indication Chronic pruritus of unknown origin (CPUO) Indication Chronic pruritus of unknown origin (CPUO) Phase Phase 3 Phase Phase
Slide 65: Neuroscience
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Neuroscience Financial performance Innovation: Clinical trials Neuroscience > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncology > I n
Slide 66: Del-desiran – siRNA DMPK knockdown
Content Del-desiran – siRNA DMPK knockdown Click below to navigate through the document Company overview NCT06411288 HARBOR (CEWF980A12301) Financial review Indication Myotonic Dystrophy Type 1 (DM1) Phase Phase 3 Conclusions Patients 159 Primary Hand function – video Hand Opening Time (vHOT) Append
Slide 67: Del-brax – siRNA DUX4 knockdown
Content Del-brax – siRNA DUX4 knockdown Click below to navigate through the document Company overview NCT07038200 FORTITUDE-3 (CDWH213A12301) Financial review Indication Facioscapulohumeral Muscular Dystrophy (FSHD) Phase Phase 3 Conclusions Patients 200 Primary Quantitative Muscle Testing (QMT) com
Slide 68: Del-zota – PMO mediated exon 44 skipping
Content Del-zota – PMO mediated exon 44 skipping Click below to navigate through the document Company overview NCT06244082 EXPLORE44OLE (CKPE179A12201) NCT07587242 SAFARI44 (CKPE179A12301) Financial review Indication Duchenne Muscular Dystrophy (DMD) Indication Duchenne Muscular Dystrophy (DMD) Phas
Slide 69: Fabhalta – CFB inhibitor
Content Fabhalta® – CFB inhibitor Click below to navigate through the document Company overview NCT06517758 APPRAISE (CLNP023Q12301) Financial review Indication Generalized Myasthenia Gravis (gMG) Phase Phase 3 Conclusions Patients 146 Primary Change from baseline to Month 6 in Myasthenia Gravis Act
Slide 70: Kesimpta – anti-CD20
Content Kesimpta® – anti-CD20 Click below to navigate through the document Company overview NCT06869785 FILIOS (COMB157Q12301) Financial review Indication Multiple Sclerosis new dosing regimen Phase Phase 3 Conclusions Patients 196 Primary Ofatumumab plasma pharmacokinetics - area under the curve, u
Slide 71: Mayzent / Kesimpta pediatric MS
Content Mayzent® – S1P1,5 receptor modulator / Kesimpta – CD20 antagonist Click below to navigate through the document Company overview NCT04926818 NEOS (CBAF312D2301) Financial review Indication Multiple Sclerosis, pediatrics Phase Phase 3 Conclusions Patients 129 Primary Annualized relapse rate (A
Slide 72: NIO752 – Tau antisense oligonucleotide
Content NIO752 – Tau antisense oligonucleotide Click below to navigate through the document Company overview NCT07498426 PRESERVE (CNIO752A12301) Financial review Indication Progressive Supranuclear Palsy Phase Phase 3 Conclusions Patients 300 Primary Change from baseline in the rPSPRS-10 score Appe
Slide 73: remibrutinib – BTK inhibitor
Content remibrutinib – BTK inhibitor remibrutinib – BTK inhibitor Click below to navigate through the document Company overview NCT05147220 REMODEL-1 (CLOU064C12301) NCT05156281 REMODEL-2 (CLOU064C12302) Financial review Indication Multiple Sclerosis, relapsing Indication Multiple Sclerosis, relapsi
Slide 74: remibrutinib – BTK inhibitor
Content remibrutinib – BTK inhibitor Click below to navigate through the document Company overview NCT07225504 REMASTER (CLOU064P12301) Financial review Indication Secondary progressive multiple sclerosis Phase Phase 3 Conclusions Patients 1275 Primary Time to 6-month confirmed disability progressio
Slide 75: Votoplam – Huntington modulator
Content Votoplam – Huntington modulator Click below to navigate through the document Company overview NCT07326709 INVEST-HD (CHTT227A12301) Financial review Indication Huntington’s Disease (HD) Phase Phase 3 Conclusions Patients 770 Primary Change from Baseline in cUHDRS score Appendix Outcome Innov
Slide 76: Oncology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Oncology Financial performance Innovation: Clinical trials Oncology > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncology > I n-market
Slide 77: 225Ac-PSMA-617 – Radioligand therapy target PSMA
Content 225Ac-PSMA-617 – Radioligand therapy target PSMA Click below to navigate through the document Company overview NCT06855277 AcTFirst (CAAA817B12301) NCT06780670 PSMAcTION (CAAA817A12201) Financial review Indication Metastatic castration-resistant prostate cancer Indication post Lu Metastatic
Slide 78: ianalumab – 1L Immune Thrombocytopenia
Content ianalumab – BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT05653349 VAYHIT1 (CVAY736I12301) Financial review Indication 1L Immune Thrombocytopenia Phase Phase 3 Conclusions Patients 225 Primary Rate of Stable Response off trea
Slide 79: iptacopan – CFB inhibitor
Content iptacopan – CFB inhibitor Click below to navigate through the document Company overview NCT05935215 APPRECIATE (CLNP023F12302) Financial review Indication Atypical haemolytic uraemic syndrome Phase Phase 3 Conclusions Patients 50 Primary Percentage of participants free of TMA manifestation d
Slide 80: Lutathera – Radioligand therapy target SSTR
Content Lutathera® – Radioligand therapy target SSTR Click below to navigate through the document Company overview NCT06784752 NETTER-3 (CAAA601A62301) Financial review Indication Gastroenteropancreatic neuroendocrine tumors Phase Phase 3 Conclusions Patients 240 Primary Progression Free Survival (P
Slide 81: Pelabresib – BET Inhibitor
Content Pelabresib – BET Inhibitor Click below to navigate through the document Company overview NCT04603495 MANIFEST-2 (CDAK539A12301) NCT07357727 MANIFEST-3 (CDAK539A12303) Financial review Indication Myelofibrosis Indication Myelofibrosis Phase Phase 3 Phase Phase 3 Conclusions Patients 430 Patie
Slide 82: Pluvicto – Radioligand therapy target PSMA
Content Pluvicto® – Radioligand therapy target PSMA Click below to navigate through the document Company overview NCT05939414 PSMA-DC (CAAA617D12302) Financial review Indication Oligometastatic prostate cancer Phase Phase 3 Conclusions Patients 450 Primary Metastasis Free Survival (MFS) Appendix Out
Slide 83: luxdegalutamide – Androgen receptor protein degrader
Content luxdegalutamide – Androgen receptor protein degrader Click below to navigate through the document Company overview NCT07047118 LuxAR-02 (CJSB462B12201) NCT06991556 LuxAR-03 (CJSB462C12201) Financial review Indication Metastatic castration resistant prostate cancer Indication Metastatic hormo
Slide 84: Vijoice – PI3Ki
Content Vijoice® – PI3Ki Click below to navigate through the document Company overview NCT05948943 EPIK-L1 (CBYL719P12201) Financial review Indication Lymphatic Malformation Phase Phase 2/3 Conclusions Patients 232 Primary Stage 2: Radiological response rate at Week 24 of Stage 2 (adult and pediatri
Slide 85: In-market Brands & Global Health
Content Click below to navigate through the document Company overview Financial review In-market Brands Conclusions Appendix In-market Brands Innovation: Pipeline overview & Global Health Financial performance Innovation: Clinical trials & Global Health > C ardiovascular, Renal and Metabolic > I mmu
Slide 86: Ganaplacide+lumefantrine – malaria
Content Ganaplacide+lumefantrine – Non-artemisinin Click below to navigate plasmodium falciparum inhibitor through the document Company overview NCT05842954 KALUMA (CKLU156A12301) Financial review Indication Malaria, uncomplicated Phase Phase 3 Conclusions Patients 1720 Primary PCR-corrected adequat
Slide 87: Rydapt – Multi-targeted kinase inhibitor
Content Rydapt® – Multi-targeted kinase inhibitor Click below to navigate through the document Company overview NCT03591510 (CPKC412A2218) Financial review Indication Acute myeloid leukemia, pediatrics Phase Phase 2 Conclusions Patients 22 Primary Occurrence of dose limiting toxicities Appendix Outc
Slide 88: EDI048
Content EDI048 Click below to navigate through the document Company overview NCT07249463 CRYPTONITE (CEDI048A12201) Financial review Indication Cryptosporidiosis infection Phase Phase 2 Conclusions Patients 80 Primary Average stool grade after the initiation of EDI048 or placebo treatment Appendix O
Slide 89: Abbreviations
Content Click below to navigate through the document Abbreviations Company overview Financial review Abbreviation Full form Abbreviation Full form Abbreviation Full form 1L First-line EMA European Medicines Agency NMPA National Medical Products Administration (China) Conclusions 2L Second-line ESC E
Slide 90: References (1/2)
Content Click below to navigate through the document References (1/2) Company overview Financial review Kisqali ® (slide 6 references) 1 IQVIA Market Sizing Monthly Report, Aug 2026, rolling 3 months; Data lag ~ 2 months. Conclusions 2 eBC DE & UK NBRx monthly share from BEST as of Jun 2026 and Jul
Slide 91: References (2/2)
Content Click below to navigate through the document References (2/2) Company overview Financial review Scemblix® (slide 11 references) 1 US IQVIA CML market sizing report, Sep 2026 (up to Jun 2026 data month); Nomenclature changed to more accurately reflect the IQVIA patient-level data used in this